GlassScriptPhysician profile
Chike Floyd Okolocha
NPI 1851915342
$6,507.29
in general payments reported to CMS, 2019-2025
40 companies · $3,658 in 2025
The $3,658 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $213 · 2024: $2,636 · 2025: $3,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,267 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,267.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,321.37 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $858.28 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $684.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $411.01 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $364.30 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.46 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $297.24 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $260.47 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $228.99 | 2024-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.39 | 2023-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $122.32 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $119.08 | 2023-2025 | |
| Astellas Pharma US INC | $117.95 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $108.58 | 2023-2025 | |
| Radius Health, INC. | $106.53 | 2024-2025 | Tymlos |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.61 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $92.36 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $75.80 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $72.82 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Almatica Pharma LLC | $71.59 | 2025 | Loreev Xr |
| Ironwood Pharmaceuticals, INC | $67.26 | 2024 | |
| Vanda Pharmaceuticals INC. | $63.82 | 2025 | Fanapt |
| Esperion Therapeutics, INC. | $60.63 | 2024 | Nexletol |
| Dexcom, INC. | $52.19 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $49.90 | 2024 | Unithroid |
| Idorsia Pharmaceuticals US INC | $41.42 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $36.98 | 2024 | Gvoke Hypopen |
| Nevro Corp. | $26.75 | 2024 | Senza |
| Biotronik Nro, INC. | $24.25 | 2025 | Prospera |
| Supernus Pharmaceuticals, INC. | $21.66 | 2025 | Qelbree, Tlando, Xyosted |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.64 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.83 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $18.92 | 2024 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $17.10 | 2024 | |
| Edwards Lifesciences Corporation | $16.23 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Halozyme INC | $16.23 | 2023 | |
| Antares Pharma, INC. | $15.93 | 2024 | Xyosted |
| Ardelyx, INC. | $15.03 | 2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $14.90 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.01 | 2025 | Xhance, Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chike Okolocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.